News
DTIL
5.70
+26.67%
1.20
Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst
Benzinga · 20h ago
Advancements in Precision BioSciences’ Gene Editing Platform Bolster Buy Rating
TipRanks · 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 1d ago
Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
Precision Bio rises after Phase 1/2 data for gene editing therapy in OTC deficiency
Seeking Alpha · 1d ago
PRECISION BIOSCIENCES INC <DTIL.O>: BMO RAISES TO OUTPERFORM FROM MARKET PERFORM 
Reuters · 1d ago
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
Benzinga · 1d ago
Promising Clinical Outcomes and Future Growth Potential: Buy Rating for Precision BioSciences
TipRanks · 1d ago
Precision Biosciences Raised to Outperform From Market Perform by BMO Capital
Dow Jones · 1d ago
Precision Biosciences Price Target Maintained With a $34.00/Share by BMO Capital
Dow Jones · 1d ago
BMO Capital Upgrades Precision BioSciences to Outperform, Maintains Price Target to $34
Benzinga · 1d ago
Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
Precision BioSciences upgraded to Outperform from Market Perform at BMO Capital
TipRanks · 1d ago
Strong Buy Recommendation for Precision BioSciences: Promising Clinical Data and Favorable Valuation
TipRanks · 1d ago
Precision Biosciences' ECUR-506 Achieves Complete Response In OTC Deficiency Patient
NASDAQ · 1d ago
Precision Biosciences' Partner iECURE Has Reported Clinical Efficacy And Safety Data In The First Patient Dosed With ECUR-506 In The Phase 1/2 OTC-HOPE Study
Benzinga · 2d ago
PRECISION BIOSCIENCES ANNOUNCES COMPLETE CLINICAL RESPONSE IN FIRST INFANT DOSED BY PARTNER IECURE IN ONGOING PHASE 1/2 CLINICAL TRIAL IN ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY
Reuters · 2d ago
PRECISION BIOSCIENCES INC - ECUR-506 GENERALLY WELL TOLERATED WITH NO SIGNIFICANT SAFETY CONCERNS
Reuters · 2d ago
IECURE REPORTS COMPLETE CLINICAL RESPONSE IN FIRST INFANT DOSED WITH ITS IN VIVO GENE EDITING CANDIDATE ECUR-506 IN AN ONGOING PHASE 1/2 CLINICAL TRIAL IN ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY
Reuters · 2d ago
PRECISION BIOSCIENCES INC - EXPECTS CASH RUNWAY INTO SECOND HALF OF 2026
Reuters · 3d ago
More
Webull provides a variety of real-time DTIL stock news. You can receive the latest news about Precision Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About DTIL
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).